Literature DB >> 1303142

[Leu31-Pro34] neuropeptide Y identifies a subtype of 125I-labeled peptide YY binding sites in the rat brain.

D R Gehlert1, S L Gackenheimer, D A Schober.   

Abstract

Subtypes of the neuropeptide Y (NPY) receptor in the rat brain were identified by the use of the selective Y-1 analog, [Leu34-Pro34] NPY. In rat brain homogenate binding studies, [Leu31-Pro34] NPY was found to produce a partial inhibition of 100 pM 125I-labeled peptide YY (PYY) binding with a plateau at 50-1000 nM [Leu31-Pro34] NPY resulting in a 70% inhibition of binding. The C-terminal fragment NPY 13-36, a putative Y-2 agonist, exhibited very little selectivity in rat brain homogenates. Scatchard analysis of 125I-labeled PYY binding to rat brain homogenate yielded biphasic plots with Kd values of 40 and 610 pM. Inclusion of 100 nM [Leu31-Pro34] NPY was found to eliminate the low affinity component of 125I-labeled PYY binding leaving a single, high affinity binding site with a Kd of 68 pM. In autoradiographic studies, displacement curves indicated that [Leu31-Pro34] NPY completely inhibited binding in the cerebral cortex with little effect on the binding in the hypothalamus. On the other hand NPY 13-36 inhibited binding in the hypothalamus at low concentrations but required higher concentrations to inhibit binding in the cerebral cortex. Other brain regions such as the hippocampus, appeared to contain both subtypes. Subsequent to these studies, a quantitative autoradiographic map was conducted using 50-100 pM 125I-labeled PYY in the presence and absence of [Leu31-Pro34] NPY which produced a selective displacement of binding in certain distinct brain regions. These areas included the cerebral cortex, certain thalamic nuclei and brainstem while ligand binding was retained in other brain regions including the zona lateralis of the substantia nigra, lateral septum, nucleus of the solitary tract and the hippocampus. Numerous brain regions appeared to contain both receptor subtypes. Therefore, the Y-1 and Y-2 receptor subtypes exhibited a somewhat distinct distribution in the brain. In addition, 125I-labeled PYY appears to label the Y-2 receptor with relatively higher affinity when compared to the Y-1 receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1303142     DOI: 10.1016/0197-0186(92)90067-2

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  10 in total

1.  [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors.

Authors:  Y Dumont; R Quirion
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  Marked decrease of neuropeptide Y Y2 receptor binding sites in the hippocampus in murine prion disease.

Authors:  M Diez; J Koistinaho; S J Dearmond; D Groth; S B Prusiner; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 3.  What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands.

Authors:  Ahmed M Elmansi; Mohamed E Awad; Nada H Eisa; Dmitry Kondrikov; Khaled A Hussein; Alexandra Aguilar-Pérez; Samuel Herberg; Sudharsan Periyasamy-Thandavan; Sadanand Fulzele; Mark W Hamrick; Meghan E McGee-Lawrence; Carlos M Isales; Brian F Volkman; William D Hill
Journal:  Pharmacol Ther       Date:  2019-02-10       Impact factor: 12.310

4.  Differential regulation of GABA release and neuronal excitability mediated by neuropeptide Y1 and Y2 receptors in rat thalamic neurons.

Authors:  Q Q Sun; G Akk; J R Huguenard; D A Prince
Journal:  J Physiol       Date:  2001-02-15       Impact factor: 5.182

5.  Neuropeptide Y receptors differentially modulate G-protein-activated inwardly rectifying K+ channels and high-voltage-activated Ca2+ channels in rat thalamic neurons.

Authors:  Q Q Sun; J R Huguenard; D A Prince
Journal:  J Physiol       Date:  2001-02-15       Impact factor: 5.182

6.  The cloned rat pancreatic polypeptide receptor exhibits profound differences to the orthologous receptor.

Authors:  I Lundell; M A Statnick; D Johnson; D A Schober; P Starbäck; D R Gehlert; D Larhammar
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

7.  Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY.

Authors:  Yvan Dumont; Mira Thakur; Annette Beck-Sickinger; Alain Fournier; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

8.  Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro.

Authors:  S Greber; C Schwarzer; G Sperk
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

9.  Expression and characterization of the neuropeptide Y Y5 receptor subtype in the rat brain.

Authors:  Y Dumont; A Fournier; R Quirion
Journal:  J Neurosci       Date:  1998-08-01       Impact factor: 6.167

Review 10.  NPY and Gene Therapy for Epilepsy: How, When,... and Y.

Authors:  Stefano Cattaneo; Gianluca Verlengia; Pietro Marino; Michele Simonato; Barbara Bettegazzi
Journal:  Front Mol Neurosci       Date:  2021-01-22       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.